LifeMD Aktie News

LifeMD is rated a buy with an FY 2026 target price of ~$6, implying over 85% upside from current levels. LFMD's shift to a pure-play telehealth model, divesting WorkSimpli, and integrating in-house pharmacy capabilities are expected to drive growth and margin expansion. Regulatory approval for 503-A compounding pharmacy and the Novo Nordisk Wegovy partnership are highlighted as key catalysts fo...

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of LifeMD, Inc. (NASDAQ: LFMD) breached their fiduciary duties to shareholders.

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced the closing of a new senior secured revolving credit facility (“RCF”) with Citizens Bank, N.A. (“Citizens”). The facility has a maturity date of January 2, 2029 and provides for up to $50 million of total availability consisting of $30 millio...

Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options

NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on Januar...

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced it has been recognized on both the 2025 Deloitte Technology Fast 500™ and the inaugural TIME's America's Growth Leaders of 2026 lists. These distinguished awards reflect LifeMD's continued revenue growth, financial stability, and em...

LifeMD, Inc. ( LFMD ) Q3 2025 Earnings Call November 17, 2025 4:30 PM EST Company Participants Justin Schreiber - Chairman & CEO Marc Benathen - Chief Financial Officer Conference Call Participants David Larsen - BTIG, LLC, Research Division Steven Valiquette - Mizuho Securities USA LLC, Research Division Anderson Schock - B. Riley Securities, Inc., Research Division Sarah James - Cantor Fitzge...

Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million. Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted EBITDA increased 30% to $2.9 million.